Zoetis is the largest global animal health company, holding a significant market share. Its strong brand recognition and extensive portfolio of products for livestock and pets give it a competitive edge. Zoetis has demonstrated strong and consistent financial performance, with steady revenue and profit growth. This stability is attractive for long-term investors seeking reliable returns. Zoetis offers a wide range of products including vaccines, medicines, diagnostics, and genetic tests for both livestock and companion animals. This diversification helps mitigate risk and ensures multiple revenue streams. The pet care market has been growing steadily, driven by increasing pet ownership and higher spending on pet health and wellness. Zoetis is well-positioned to benefit from this trend with its extensive range of pet health products. Zoetis invests heavily in research and development, continuously bringing new and innovative products to market. This focus on innovation helps maintain its competitive edge and drives future growth. Zoetis has a strong international presence and continues to expand into new markets, particularly in emerging economies where demand for animal health products is increasing. The company has a history of strategic acquisitions that enhance its product offerings and market reach. These acquisitions help drive growth and improve the company's competitive position. Zoetis is committed to sustainable business practices, which can enhance its reputation and appeal to socially responsible investors. This includes efforts in environmental sustainability and ethical animal treatment. The animal health industry tends to be more resilient during economic downturns compared to other sectors, as spending on animal health is often considered essential. This stability can provide a buffer against economic volatility. Zoetis has a strong and experienced management team with a clear vision for long-term growth and value creation. Effective leadership is crucial for navigating challenges and capitalizing on opportunities.
$ZTS - Zoestis, an animal healthcare company looks fairly valued.
PE ratio: 29.65
Dividend Payout ratio: 29.98%
FCF payout ratio: 49.29%
5 yr revenue CAGR: +7.96%
5 yr EPS CAGR: +11.41%
5 yr FCF CAGR: +3.18%
5 yr dividend CAGR: +24.37%
FCF yield: 2.05%
FCF margin: 18.94%
12 months Analyst avg. price target: $209.33 (22.35% upside)
$ZTS: Since 2010, the EPS has been growing by double digits.
5 yr EPS CAGR: +11.41%
10 yr EPS CAGR: +17.53%
EPS growth forecast for
2024: +14.82% (19 analysts)
2025: +10.67% (19 analysts)
2026: +9.71% (14 analysts)
$ZTS: Since 2010, the revenue has been growing.
5 yr revenue CAGR: +7.96%
10 yr revenue CAGR: +6.48%
Revenue growth forecast for
2024: +8.19% (19 analysts)
2025: +6.17% (19 analysts)
2026: +6.61% (14 analysts)
$ZTS - The net income has been growing by double digits. 5 yr net income CAGR: +10.42% 10 yr net income CAGR: +16.61% Net income is increasing while the outstanding shares are decreasing which indicates a positive financial trend for the company, leading to an increase in EPS and share buybacks.
$ZTS - The debt-to-equity is dropping fast.
$ZTS - so far is an outstanding dividend grower. 5 yr dividend CAGR: +24.37% 10 yr dividend CAGR: +22.63% Dividend Payout ratio: 29.98% FCF payout ratio: 49.29%
